Skip Navigation

Annals of Oncology 2007 18(Supplement 12):xii8-xii14; doi:10.1093/annonc/mdm533
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Di Leo, A.
Right arrow Articles by Biganzoli, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Leo, A.
Right arrow Articles by Biganzoli, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

symposium articles

New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer

A. Di Leo1,*, W. Claudino1, D. Colangiuli3, S. Bessi2, M. Pestrin1 and L. Biganzoli1

1 ‘Sandro Pitigliani’ Medical Oncology Unit
2 Pathology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
3 Magnetic Resonance Center, Scientific Pole, University of Florence, Sesto Fiorentino, Florence, Italy, and FiorGen Foundation, Sesto Fiorentino, Florence, Italy

* Correspondence to: Dr A. Di Leo, ‘Sandro Pitigliani’ Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza dell'Ospedale 2, 59100, Prato, Italy. Tel: +39-0574/434766; Fax: +39-0574/29798; E-mail: adileo{at}usl4.toscana.it

Despite significant improvements in the treatment and outcomes of early-stage breast cancer, the quest continues to find biological and molecular markers that would enable earlier diagnosis or better prediction of treatment efficacy and toxicity. Metabolomics—the latest and one of the most exciting of the ‘omic’ sciences—has shown early promise as a non-invasive diagnostic aid in ovarian cancer, and may allow the detection of subtle metabolic changes that could have diagnostic, prognostic or predictive value in breast cancer. Routine monitoring of circulating tumour cells (CTCs) has also been advocated as a novel means of detecting breast cancer progression earlier, and identifying alterations in tumour cells that might signal the need for therapy changes. Ongoing studies should help to answer important questions relating to the use of metabolomics and CTC evaluation as new strategies to monitor cancer progression and identify markers of chemotherapy activity and toxicity.

Key words: breast cancer, metabolomics, metabolic profiles, circulating tumour cells, molecular markers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.